NCT01011374View on ClinicalTrials.gov

Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion

PHASE1UnknownINTERVENTIONAL

Enrollment

45

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2013

Conditions

Venous Retinal Branch OcclusionCentral Retinal Vein OcclusionRetinal Vein OcclusionDepression

Interventions

DRUG

ranibizumab (Lucentis)

0.5 mg, administered intravitreally every 4 weeks

Trial Locations (1)

44122

Retina Associates of Cleveland, Cleveland

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Retina Associates of Cleveland, Inc

OTHER